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Abstract
Background: Aside from well-established inflammatory mediators adipokines have recently been found to play an
important role in a variety of immunologic diseases. Therapeutic plasma exchange (TPE) is an established treatment
modality for the acute removal of pathophysiological relevant disease mediators. The aim of this study was to
determine adipokine removal during TPE therapy.
Methods: 21 Caucasian patients (10 females, 11 males) with an indication for TPE using albumin as exchange fluid
received two consecutive TPE sessions. Blood samples for measurement of resistin, leptin, sICAM-1, sCD40L, MCP-1,
and sTNF-R were drawn before and at the end of each TPE session. Samples from the total removed plasma were
collected at the end of every treatment.
Results: We found a significant reduction in pre- vs. post-TPE plasma concentrations for sICAM-1 (517 ± 246 vs. 260
± 159 ng/ml, p < 0.0001), sTNF-R (8.1 ± 6.4 vs. 5.7 ± 3.9 ng/ml, p < 0.05), and resistin plasma levels (14.3 ± 6.9 vs. 9.5 ±
4.7 ng/ml, p < 0.001). Solely sICAM-1 reduction persisted for 25 ± 5 h between the first and second TPE treatment,
while the other investigated mediators increased to baseline levels. Substantial amounts of all measured mediators
could be recovered from the removed plasma.
Conclusions: TPE provides a persistent reduction in sICAM-1 levels and temporarily affects several adipokine and
cytokine plasma levels. Our findings are of importance not only for the interpretation of blood levels of cytokines in
patients undergoing TPE but provide solid evidence that TPE markedly decreases sICAM-1.
Background
Therapeutic plasma exchange (TPE) is an extracorporeal
treatment modality separating and removing blood plasma
and replacing it with a protein containing fluid such as
albumin [1]. It is performed in an increasing number of
mainly immunologic disorders to remove substances with
a high molecular weight such as antibodies, antibody-
antigen complexes, and paraproteins [2]. In addition, due
to the unselective removal of plasma, other plasma com-
ponents like inflammatory mediators get eliminated as
well. This may play a role in inflammatory states, as for
example sepsis with multi-organ failure, where TPE has
been employed [3–5]. So far, data regarding the removal
of inflammatory mediators during TPE are scarce. This is
especially true for adipokines, which have lately been
found to mediate inflammatory processes. The adipose
tissue, the origin of these substances, is described as the
body’s largest endocrine active organ, which contributes
to a chronic low-grade inflammatory state in obese pa-
tients [6]. In this regard, the adipokine leptin is known
to influence mammals’ food intake and energy balance
as well as inflammatory processes after stimulated by
cytokines or lipopolysaccharides [7–9]. Intercellular Ad-
hesion Molecule 1 (ICAM-1) orchestrates the migration
of inflammatory cells [10]. sICAM-1, the soluble form of
ICAM-1, has been shown to be elevated and of patho-
physiological importance in immunologic disorders as
vasculitis [11], a condition for which TPE is used on a
regular basis [12]. Besides their key role in regulating in-
flammatory processes, adipokines and cytokines are also
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biomarkers in numerous disorders, where their plasma
level is related to the disease activity like in systemic lupus
erythematodes [13, 14]. In general, sICAM-1 is viewed as
a biomarker for endothelial activation [15].
The aim of this study was to investigate the effect of
TPE on inflammatory markers / adipokines, to quantify
their removal, and to assess their rebound after the
treatment.
Methods
The study was approved by the local Ethics Committee
of Hannover Medical School, Germany protocol # 5343.
All patients gave written informed consent before en-
rolment into the study. We started the study with 21
Caucasian patients (10 females and 11 males with a
mean age of 51.6 ± 13.5 years and a BMI of 25.1 ±
5.0 kg/m2) with indication for TPE due to various dis-
eases including humoral rejection after solid organ
transplantation, Guillain-Barré syndrome, monoclonal
gammopathy, multiple sclerosis, rapid progressive glomer-
ulonephritis, polyneuritis, microscopic polyangitis, and
cryoglobulinemia. Further patients’ characteristics and de-
tails of the procedure are described elsewhere [16].
Every patient received two consecutive TPE sessions
during the study. Plasma exchange therapy was performed
using either the Spectra Optia® (TerumoBCT Inc., USA)
or the Octo Nova® (DIAMED Medizintechnik GmbH,
Germany) apheresis system. Anticoagulation was applied
either by heparin or citrate. The prescribed dose of ex-
change volume of every TPE treatment was 1.1-times the
individual calculated total plasma volume, using the
Nadler-Allen equation.
A substitute fluid with 5 % albumin concentration was
used in every treatment. Blood samples for measure-
ment of different adipokines / obesity markers as resis-
tin (12.5 kDa), leptin (16 kDa), sICAM-1 (80–110 kDa),
soluble CD40 ligand (sCD40L, 39 kDa), monocyte
chemoattractant protein-1 (MCP-1, 13 kDa), soluble
tumor necrosis factor receptor (sTNF-R, 60 kDa), and
routine chemistry were drawn before (pre-TPE) and at
the end (post-TPE) of the first and second TPE session.
Samples at the end of each TPE treatment were col-
lected before the rinse back of the blood. Additionally,
plasma samples from the waste bags were drawn after
each treatment. Blood samples were immediately cooled
on ice, centrifuged at 1500 g, and 4 °C for 10 min. Plasma
samples were stored in 1 ml aliquots at −80 °C until fur-
ther use.
Analysis of plasma adipokines and cytokines
Leptin, resistin, soluble CD40 ligand (sCD40L), sICAM-
1, soluble tumor necrosis factor receptor (sTNF-R), and
monocyte chemoattractant protein 1 (MCP-1) were ana-
lysed using the eBioscience® FlowCytomix™ Human
Obesity 9plex Kit (Bender MedSystems GmbH, Austria)
following the manufacturer’s instructions. A standard
protein dilution and human plasma samples were incu-
bated with a Bead and Conjugate Mixture for two hours.
After washing with assay buffer, a Streptavidin-PE Solu-
tion was added and incubated for one hour. Subse-
quently, samples and standard protein dilutions were
washed twice, re-suspended in assay buffer, and analysed
by flow cytometry using LSR Fortessa (BD Biosciences,
San Diego, USA) with FlowCytomix Pro Software
(Bender MedSystems GmbH, Vienna, Austria).
Statistical analysis
We used GraphPad Prism 6 (GraphPad Software, Inc.,
La Jolla, USA) for statistical analysis. Pre- and post-TPE
levels of all treatments were compared suing the student
T-test. This analysis was conducted in the whole study
population as well as woman and men separately, the
significance level was set at p < 0.05.
Results
All enrolled patients completed the two study TPE treat-
ments. The exchanged plasma volume over all treatment
sessions was 3570 ± 589 ml, which was 1.1 ± 0.1-times
the individual calculated plasma volume. The average
time period between the first and second therapy session
was 25 ± 5 h.
sICAM-1
Evaluating all TPE sessions (1st and 2nd) plasma levels of
sICAM-1 were reduced by ~ 50 % (from 517 ± 246 pre-
TPE to 260 ± 159 ng/ml post TPE, p < 0.0001). Separate
analysis of the 1st TPE session showed a decrease of
sICAM-1 from 615 ± 261 to 291 ± 173 ng/ml, p < 0.0001.
Despite a rebound from 291 ± 173 after the 1st TPE to
418 ± 189 ng/ml (p < 0.05) before the 2nd these levels
were still lower than the ones before the 1st treatment
(418 ± 189 ng/ml vs. 615 ± 261, p < 0.01), suggesting a
prolonged reduction effect of TPE on sICAM-1. A total
amount of 1.3 ± 0.9 mg sICAM-1 per treatment was re-
covered from the total removed collected plasma
(Figs. 1a and 2a).
sCD40L
There was neither a significant decrease in soluble CD40
Ligand plasma levels comparing all pre-TPE and post-TPE
levels (4.4 ± 2.3 vs. 3.4 ± 1.7 ng/ml, n.s.) nor analysing the
effect of the 1st TPE alone (4.8 ± 2.7 vs. 3.6 ± 1.8 ng/ml,
n.s.). Furthermore, no significant differences of sCD40L
neither in pre TPE plasma levels between the two treat-
ment sessions (pre-TPE 1 vs. pre-TPE 2: 4.8 ± 2.7 vs. 3.9 ±
1.7 ng/ml, n.s.) nor from the end of the 1st to the begin-
ning of the 2nd treatment (3.6 ± 1.8 vs. 3.9 ± 1.7 ng/ml,
n.s.) could be detected. We found a total amount of 1.6 ±
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1.8 μg sCD40L in the collected removed plasma. (Figs. 1b
and 2b).
sTNF-R
There was a significant decrease in soluble TNF-R compar-
ing all pre-TPE to post-TPE plasma levels (8.1 ± 6.4 vs. 5.7
± 3.9 ng/ml, p < 0.05). We found a total amount of 21.3 ±
18.6 μg sTNF-R in the collected removed plasma. However,
there was no significant decrease in TNF-R plasma levels
comparing pre to the post-TPE levels of the 1st TPE treat-
ment alone (8.3 ± 6.7 vs. 5.6 ± 3.8 ng/ml, n.s.). There was
also no significant difference in pre-TPE plasma levels of
sTNF-R between the two treatment sessions (8.3 ± 6.7 vs.
7.8 ± 6.3 ng/ml, n.s.) nor a sTNF-R increase from the end
of the 1st to the beginning of the 2nd treatment (5.6 ± 3.8 vs.
7.8 ± 6.3 ng/ml, n.s.) (Figs. 1c and 2c).
MCP-1
There was neither a significant decrease in MCP-1 com-
paring all pre-TPE to post-TPE plasma levels (1.4 ± 1.7 vs.
1.2 ± 1.3 ng/ml, n.s.) nor looking at the 1st TPE alone
(1.5 ± 1.7 vs. 1.3 ± 1.4 ng/ml, n.s.). Despite the lack of ef-
fect of TPE on plasma levels we found a total amount of 2.1
± 2.9 μg MCP-1 in the exchanged plasma. (Figs. 1d and 2d).
Resistin
Resistin was significantly reduced during TPE comparing
all pre- and post-TPE sessions (14.3 ± 6.9 vs. 9.5 ±
4.7 ng/ml, p < 0.001) as well as looking at the first TPE
alone (14.2 ± 6.9 vs. 9.4 ± 4.5 ng/ml, p < 0.05). A total
amount of 26.5 ± 16.3 μg resistin was detected in the re-
moved plasma. There was a significant rebound from
the end of the 1st to the beginning of the 2nd treatment
(9.4 ± 4.5 vs. 14.5 ± 7.1 ng/ml, p < 0.01). However, the
resistin plasma levels prior to the first and second treat-
ment did not differ significantly (14.2 ± 6.9 vs. 14.5 ±
7.1 ng/ml, n.s.) (Figs. 1e and 2e).
Leptin
There was neither a significant reduction of leptin plasma
by TPE comparing all pre-TPE and post-TPE levels (172.8
± 169.4 vs. 122.4 ± 134.2 ng/ml, n.s.) nor analysing the
Fig. 1 Pre- and post-TPE plasma levels (left y-axis) of adipokines and cytokines levels summarizing all treatments. Total amount of the respective
compounds in the waste bag is shown on the right y-axis. Removal of each investigated molecule is visualized in separated panels (a: sICAM-1, b:
sCD40L, c: sTNF-R, d: MCP-1, e: Resistin, f: Leptin)
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effect of the 1st TPE separately (178.5 ± 159.4 vs. 130.5 ±
135.5 ng/ml, n.s.). We found a total amount of 45.2 ±
49.2 μg leptin in the total removed plasma. No significant
increase in leptin plasma levels between the end of the 1st
treatment and the start of the 2nd TPE (130.5 ± 135.5 vs.
167.1 ± 181.8 ng/ml, n.s.). (Figs. 1f and 2f).
Gender effects
Interestingly, in a separate analysis on the effect of gen-
der the female patients revealed a resistin reduction dur-
ing the 1st TPE treatment (pre-TPE 1women vs. post-TPE
1women: 17.1 ± 5.7 vs. 11.8 ± 3.8 ng/ml, p < 0.05) as well
as resistin rebound (post-TPE 1women vs. pre-TPE
2women: 11.8 ± 3.8 vs. 17.3 ± 5.8 ng/ml, p < 0.05) while
men did not. Plasma resistin levels were also significantly
higher in women as compared to the male patients before
and after TPE (pre-TPEwomen vs. pre-TPEmen: 17.2 ± 5.6
vs. 11.2 ± 6.9 ng/ml, p < 0.01; post-TPEwomen vs. post-
TPEmen: 11.8 ± 3.9 vs. 7.1 ± 4.3 ng/ml, p < 0.001).
Discussion
This study shows for the first time that sICAM-1, sTNF-
R, and resistin plasma levels are significantly reduced by
TPE treatment and quantifies the amount of these sub-
stances in the total collected removed plasma. While the
effect for sICAM-1 persisted for 25 ± 5 h, all other inves-
tigated markers increased back to baseline in that period
of time. These results can also be found in a subgroup
analysis, evaluating patients with BMI > 25 kg/m2 and
with a BMI < 25 kg/m2 seperatey. There is a gender spe-
cific effect of TPE on resistin plasma levels.
There are several aspects to consider in the interpret-
ation of our results. It seems unlike that, the difference in
prolonged serum level decrease between the investigated
Fig. 2 Time course of adipokine and cytokine plasma levels. Time between end of 1st treatment (post TPE 1) and beginning of 2nd treatment (pre-TPE 2)
was 25 ± 5 h. Plasma levels of each investigated molecule are visualized in separated panels (a: sICAM-1, b: sCD40L, c: sTNF-R, d: MCP-1, e: Resistin, f: Leptin)
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substances is due their difference in molecular size. All in-
vestigated substances, which range from 12.5 to 89 kDa
are clearly below the molecular cut-off of the TPE,
i.e.1000 kDa.. Different serum half-life times and different
volumes of distribution seem more likely to play a role in
the different effects of TPE in the examined markers. This
is best epitomized by leptin, which it is not significantly al-
tered by TPE. In the human body it has a very short half-
life of 25 min [17]. The half-life of sICAM-1, the molecule
which was markedly and prolonged lowered by TPE, is
only ill defined as it is highly variable and changes with
the underlying disease. However, induced sICAM-1 re-
lease in human epithelial cells needs up to 24 h to achieve
a steady state concentration [18], therefore the sICAM-1
serum dynamic is presumably slower than the one of lep-
tin. Adipokine serum levels, except resistin, were generally
higher in our patients than in healthy controls described
in the literature.
While the effect of TPE on immunoglobulins and
immune-complexes [19] or even cardiac markers like
troponin and BNP [16] has been shown, data on the ef-
fect of other pathophysiologically important mediators
are scarce. The most interesting compound in our ana-
lysis was sICAM-1. It increases in different inflammatory
diseases like vasculitis or psoriasis arthritis [20]. It is be-
lieved that the soluble form of ICAM-1 has an active im-
munologic role due to its interaction with lymphocyte
function-associated antigen (LFA-1) [11]. Compared to
healthy subjects reported in the literature, the observed
plasma concentrations of our patients was markedly ele-
vated. This is in line with previous studies in patients
with inflammatory diseases [21]. In ANCA-positive renal
vasculitis Tesar et al. proved a significant decrease of
sICAM-1 in the TPE treatment period [22]. In our study,
we see a marked effect on TPE on sICAM in all patients
including those with antibody-mediated rejection after
renal transplantation. This might be of clinical importance
as sICAM-1 levels significantly correlate with mortality in
renal transplant recipients [23]. To our knowledge this is
the first time both, a significant decrease of sICAM-1
levels in the patient’s blood after TPE and the eliminated
whole amount of sICAM-1 in the waste bag, are shown.
Soluble TNF-R is important in inflammatory condi-
tions like spondyloarthritis and is associated with delir-
ium in critically ill patients [24, 25]. sTNF-R levels are
increased in our patient group compared with the gen-
eral population [26]. In the present study we observed a
significant decrease in sTNF-R levels of 30 % during TPE
treatment. This finding is remarkable, as even extracor-
poreal liver support systems as MARS™ (Molecular Ad-
sorbent Recirculating System) or Prometheus™ were not
able to lower sTNF-R levels [27]. However, the sTNF-R
levels did not differ in pre TPE levels between the 1st and
the 2nd treatment suggesting a short lived effect on plasma
levels, which does not exclude a potential clinical benefit
in diseases like spondyloarthritis.
The adipokine leptin could not be lowered by TPE.
The role of leptin in inflammatory diseases is controver-
sial. It might be a marker of disease activity in Behçet’s
syndrome and is elevated in patients with systemic lupus
erythematodes [28, 29]. Leptin also seems to decrease in
patients with active ANCA associated vasculitis [30]. It
is possible that leptin plays an important role in several
inflammatory conditions. Yet, we found no significant
decrease in leptin plasma levels in our study.
The role of resistin in inflammation is also a matter of
debate. While high resistin levels are associated with
rheumatoid arthritis, coronary heart disease and insulin re-
sistance, a low resistin plasma level may be correlated with
a high hospitalization rate in dialysis patients [31, 32].
Interestingly, the women in our study had higher resistin
plasma levels as compared to the male patients. Further-
more, resistin plasma levels decreased significantly in
women during TPE. Gender specific differences in resistin
levels have been described since the introduction of the
molecule [33]. Steppan et al. speculate in a later review
that gender differences may be due to differences in body
fat distribution or hormone levels [34]. Hormone influence
on resistin serum levels seems likely as they are approxi-
mately two times higher during premenopause compared
to peri- or postmenopause [35]. However, estradiol admin-
istration or ovariectomy did not alter resistin serum levels
in women [36]. Resistin serum levels seem to be independ-
ent from patients’ bodyweight and may be a possible risk
factor for insulin resistance [37]. In addition, resistin may
play a role in breast and endometrial cancer [38]. However,
gender specific differences in resistin serum levels are not
fully understood and cannot be further clarified by this
study, as it was not designed to do so.
Excessive body fat mass in obese patients leads to ele-
vated circulating adipokine levels especially of leptin,
resistin, and TNF-α [39, 40]. We performed a subgroup
analysis, where we divided our patients into a group with
BMI <25 (7 women, 3 men) and >25 (4 women, 7 men).
Interestingly, post TPE serum levels for resistin were sig-
nificantly higher in the lean patient group, while pre
TPE serum levels had a similar trend (pre TPE serum
levels BMI <25 vs. BMI >25 16 ng/ml ± 1.6 vs. 11.9 ±
1.3 ng/ml, p = 0.06, post TPE serum levels BMI <25 vs.
BMI >25: 10.7 ± 1.1 ng/ml vs. 7.9 ± 0.9 ng/ml, p < 0.05).
Therefore, one could postulate, that the gender specific ef-
fect on resistin serum concentrations seems to overcome
influences of body mass. However, due to the small pa-
tient number of this study, subgroup analyses could be
misleading. Leptin, one of the central adipocyte-derived
hormones, has a major influence on metabolism, immune
functions [41], and has often been associated with cell
proliferation and cancer development. A reduction of
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these mediators after therapeutic plasma exchange could
accomplish positive effects in case of an obesity-related in-
crease of adipokine levels. Furthermore, we demonstrated
that altered levels of several adipokines (e.g. resistin and
leptin) can decrease the glomerular filtration rate and in-
crease albuminuria [42].
We wish to acknowledge several limitations of our
study. Firstly, we only included patients receiving TPE
with albumin as replacement fluid as fresh frozen
plasma would have interfered with the analysis of the
biomarkers. Therefore, our results are valid for patients
treated with TPE and albumin as an exchange fluid. Fur-
thermore, underlying illnesses necessitating TPE and
other patient characteristics spanned a variety of condi-
tions. Different morbidities may affect the kinetics of the
measured marker, as well as differences in the timespan
between the treatment sessions. This could lead to an
over- or underestimation of the effects of TPE. Addition-
ally, the patient number of our study is rather small and
we did not include a follow up period, so clinical rele-
vance of this date cannot be determined.
Conclusion
In summary, the present study shows a substance- and
time-specific removal of various adipokines by TPE.
sICAM-1 is the only investigated substance, which
shows a prolonged reduction in the patients’ serum
levels by TPE. Therefore, sICAM-1 plasma levels should
be interpreted with caution in patients undergoing TPE.
Thus, apart from the removal of autoantibodies and pro-
teins levels of adipocyte tissue derived hormones are al-
tered by TPE. Depending on the specific adipokine, this
side-effect of TPE may be (dis)advantageous for the
treatment of the underlying disease.
Consent
All patients gave written informed consent before enrol-
ment into the study. A copy of the written consent is
available for review by the Series Editor of this journal.
Abbreviations
LFA-1: lymphocyte function-associated antigen; MARS™: Molecular Adsorbent
Recirculating System; MCP-1: monocyte chemoattractant protein-1; ICAM-
1: Intercellular Adhesion Molecule 1; sCD40L: soluble CD40 ligand; sTNF-
R: soluble TNF-R; TPE: Therapeutic plasma exchange.
Competing interests
JTK has received research funding from Terumo BCT for an investigator-
initiated study with unrestricted research support, i.e. no influence on the
current study. There are no other competing interests.
Authors’ contributions
CH and JTK treated and enrolled the patients. PG collected the samples. JJS,
JJ, JTK and HK evaluated the test results. All of the authors have participated
in the discussion and in writing of the submitted manuscript. All authors
read and approval the final manuscript.
Authors’ information
Not applicable
Availability of data and materials
Not applicable
Acknowledgements
We would like to thank the nursing staff of our dialysis department for the
practical support during the study. The study was supported by institutional
funds from the Department of Nephrology and Hypertension of the
Hannover Medical School.
Author details
1Department of Internal Medicine, Division of Nephrology and Hypertension,
Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
2Department of Anatomy and Cell Biology, Faculty of Medicine, Martin
Luther University Halle-Wittenberg, Halle, Germany.
Received: 30 March 2015 Accepted: 12 September 2015
References
1. Williams ME, Balogun RA. Principles of separation: indications and
therapeutic targets for plasma exchange. Clin J Am Soc Nephrol.
2014;9(1):181–90.
2. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M,
Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in
clinical practice-evidence-based approach from the Writing Committee of
the American Society for Apheresis: the sixth special issue. J Clin Apher.
2013;28(3):145–284.
3. De Simone N, Racsa L, Bevan S, Matevosyan K, Valley T, Girod C, et al.
Therapeutic plasma exchange in the management of sepsis and multiple
organ dysfunction syndrome: a report of three cases. J Clin Apher.
2014;29(2):127–31.
4. Cantaluppi V, Weber V, Lauritano C, Figliolini F, Beltramo S, Biancone L, et al.
Protective effect of resin adsorption on septic plasma-induced tubular
injury. Crit Care. 2010;14(1):R4.
5. Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, et al.
Therapeutic plasma exchange as rescue therapy in severe sepsis and septic
shock: retrospective observational single-centre study of 23 patients. BMC
Anesthesiol. 2014;14:24.
6. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and
cardiovascular disease. J Cardiol. 2014;63(4):250–9.
7. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin
reverses insulin resistance and diabetes mellitus in mice with congenital
lipodystrophy. Nature. 1999;401(6748):73–6.
8. Friedman JM, Halaas JL. Leptin and the regulation of body weight in
mammals. Nature. 1998;395(6704):763–70.
9. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, et al. Endotoxin
and cytokines induce expression of leptin, the ob gene product, in
hamsters. J Clin Invest. 1996;97(9):2152–7.
10. Long EO. ICAM-1: getting a grip on leukocyte adhesion. J Immunol.
2011;186(9):5021–3.
11. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1
(sICAM-1): an overview. Eur Cytokine Netw. 2004;15(2):91–8.
12. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et
al. Randomized trial of plasma exchange or high-dosage
methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am
Soc Nephrol. 2007;18(7):2180–8.
13. Poonpet T, Honsawek S. Adipokines: Biomarkers for osteoarthritis? World J
Orthop. 2014;5(3):319–27.
14. Aleksandrova K, Jenab M, Bueno-de-Mesquita HB, Fedirko V, Kaaks R,
Lukanova A, et al. Biomarker patterns of inflammatory and metabolic
pathways are associated with risk of colorectal cancer: results from the
European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J
Epidemiol. 2014;29(4):261–75.
15. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk
prediction. J Intern Med. 2002;252(4):283–94.
16. Tutarel O, Golla P, Beutel G, Bauersachs J, David S, Schmidt BM, et al.
Therapeutic plasma exchange decreases levels of routinely used cardiac and
inflammatory biomarkers. PLoS One. 2012;7(6):e38573.
17. Klein S, Coppack SW, Mohamed-Ali V, Landt M. Adipose tissue leptin
production and plasma leptin kinetics in humans. Diabetes. 1996;45(7):984–7.
Schmidt et al. BMC Obesity  (2015) 2:37 Page 6 of 7
18. Wang JH, Devalia JL, Sapsford RJ, Davies RJ. Effect of corticosteroids on
release of RANTES and sICAM-1 from cultured human bronchial epithelial
cells, induced by TNF-alpha. Eur Respir J. 1997;10(4):834–40.
19. Sanchez AP, Ward DM. Therapeutic apheresis for renal disorders. Semin Dial.
2012;25(2):119–31.
20. Schopf RE, Naumann S, Rehder M, Morsches B. Soluble intercellular
adhesion molecule-1 levels in patients with psoriasis. Br J Dermatol.
1993;128(1):34–7.
21. Ponthieux A, Herbeth B, Droesch S, Lambert D, Visvikis S. Age- and sex-
related reference values for serum adhesion molecule concentrations in
healthy individuals: intercellular adhesion molecule-1 and E-, P-, and L-
selectin. Clin Chem. 2003;49(9):1544–6.
22. Tesar V, Jelinkova E, Masek Z, Jirsa Jr M, Zabka J, Bartůnková J, et al.
Influence of plasma exchange on serum levels of cytokines and adhesion
molecules in ANCA-positive renal vasculitis. Blood Purif. 1998;16(2):72–80.
23. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated
soluble cellular adhesion molecules are associated with increased mortality
in a prospective cohort of renal transplant recipients. BMC Nephrol.
2011;12:23.
24. Varkas G, Van Praet L, Cypers H, Elewaut D. Spondyloarthritis and
inflammatory bowel disease. Comorbidity and treatment implications. Z
Rheumatol. 2013;72(6):524–9.
25. Ritter C, Tomasi CD, Dal-Pizzol F, Pinto BB, Dyson A, de Miranda AS, et al.
Inflammation biomarkers and delirium in critically ill patients. Crit Care.
2014;18(3):R106.
26. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al.
TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the
general population. Eur Cytokine Netw. 2006;17(3):196–201.
27. Oettl K, Stadlbauer V, Krisper P, Stauber RE. Effect of extracorporeal liver
support by molecular adsorbents recirculating system and Prometheus on
redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial.
2009;13(5):431–6.
28. Evereklioglu C, Inaloz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, et al.
Serum leptin concentration is increased in patients with Behcet’s syndrome
and is correlated with disease activity. Br J Dermatol. 2002;147(2):331–6.
29. Garcia-Gonzalez A, Gonzalez-Lopez L, Valera-Gonzalez IC, Cardona-Muñoz
EG, Salazar-Paramo M, González-Ortiz M, et al. Serum leptin levels in women
with systemic lupus erythematosus. Rheumatol Int. 2002;22(4):138–41.
30. Kumpers P, Horn R, Brabant G, Woywodt A, Schiffer M, Haller H, et al. Serum
leptin and ghrelin correlate with disease activity in ANCA-associated
vasculitis. Rheumatology (Oxford). 2008;47(4):484–7.
31. Senolt L, Housa D, Vernerova Z, Jirásek T, Svobodová R, Veigl D, et al.
Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann
Rheum Dis. 2007;66(4):458–63.
32. Chmielewski M, Cohen G, Wiecek A, Jesus CJ. The peptidic middle
molecules: is molecular weight doing the trick? Semin Nephrol.
2014;34(2):118–34.
33. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The
hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12.
34. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med.
2004;255(4):439–47.
35. Sowers MR, Wildman RP, Mancuso P, Eyvazzadeh AD, Karvonen-Gutierrez
CA, Rillamas-Sun E, et al. Change in adipocytokines and ghrelin with
menopause. Maturitas. 2008;59(2):149–57.
36. Chalvatzas N, Dafopoulos K, Kosmas G, Kallitsaris A, Pournaras S, Messinis IE.
Effect of ovarian hormones on serum adiponectin and resistin
concentrations. Fertil Steril. 2009;91(4):1189–94.
37. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma
resistin, adiponectin and leptin levels in lean and obese subjects:
correlations with insulin resistance. Eur J Endocrinol. 2003;149(4):331–5.
38. Hlavna M, Kohut L, Lipkova J, Bienertova-Vasku J, Dostalova Z, Chovanec J,
et al. Relationship of resistin levels with endometrial cancer risk. Neoplasma.
2011;58(2):124–8.
39. Kalousova M, Sulkova S, Zima T, Deppisch R, Beck W, Bednárová sV, et al.
Advanced glycation end products in hemodialyzed patients with diabetes
mellitus correlate with leptin and leptin/body fat ratio. Ren Fail.
2003;25(2):277–86.
40. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol
Diabetes. 2009;117(6):241–50.
41. Huebner L, Engeli S, Wrann CD, Goudeva L, Laue T, Kielstein H. Human NK
cell subset functions are differentially affected by adipokines. PLoS One.
2013;8(9):e75703.
42. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between
obesity and chronic kidney disease. Am J Physiol Renal Physiol.
2013;305(12):F1629–36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schmidt et al. BMC Obesity  (2015) 2:37 Page 7 of 7
